Washington, June 30 (ANI): A new study has found that women with at least three sites of cellular atypia in breast tissue are nearly eight times more likely than average women to develop breast cancer ...

While doctors almost always agree on a pathological diagnosis of invasive breast cancer, there is room for improvement when diagnosing atypia (or atypical ductal hyperplasia-ADH) and DCIS (ductal ...

Women with at least three sites of cellular atypia in breast tissue are nearly eight times more likely than average women to develop breast cancer, according to findings of a Mayo Clinic Cancer Center ...

More and more stereotactic vacuum-assisted breast biopsies (microbiopsies) are being performed in routine practice on infraclinical lesions. In a previous study on 2833 surgical biopsies performed for ...

What is the optimal dose and schedule of treatment of endometrial hyperplasia using the various progestins? Is the use of depot medroxyprogesterone a good option for treatment? Patients with ...

For the 1.6 million women in the United States who undergo breast biopsy to confirm screening mammogram or breast examination findings, a diagnosis of ductal carcinoma in situ (DCIS) or atypical ...

Improved Overall Survival in Postmenopausal Women With Early Breast Cancer After Anastrozole Initiated After Treatment With Tamoxifen Compared With Continued Tamoxifen: The ARNO 95 Study Women with ...

Please provide your email address to receive an email when new articles are posted on . Pathologists’ concordance rates for ductal carcinoma in situ and atypical hyperplasia diagnoses were generally ...

Atypical endometrial hyperplasia (AEH) occurs when the lining of the uterus is too thick and contains abnormal cells. It can cause vaginal bleeding and may progress to cause further symptoms. AEH is a ...

Please provide your email address to receive an email when new articles are posted on . Pathologists reviewing biopsy slides were less likely to confirm an initial diagnosis of atypia or ductal ...

LA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN: The ...